October 27, 2015
FDA Approves First-in-Class Oncolytic Virus Immunotherapy for the Treatment of Melanoma
MILWAUKEE, WISCONSIN – This week marks another advance in the fight against skin cancer, as the U.S. Food and Drug Administration (FDA) approved a new immune-based therapy for treating melanoma lesions in the skin and lymph nodes. Amgen’s IMLYGIC (talimogene laherparepvec) commonly referred to as T-VEC, is among a new class of agents known as oncolytic virus immunotherapies. An oncolytic virus is a virus that preferentially infects and kills cancer cells. IMLYGIC is the first therapy in this class to receive FDA approval to treat melanoma….
http://www.sitcancer.org/about-sitc/newsroom/press-releases/fda-approves-imlygic-for-melanoma
